JMP Securities Reiterates Market Outperform Rating for Lantheus (NASDAQ:LNTH)

Lantheus (NASDAQ:LNTH)‘s stock had its “market outperform” rating reiterated by equities research analysts at JMP Securities in a research note issued on Tuesday,Benzinga reports. They presently have a $112.00 price target on the medical equipment provider’s stock. JMP Securities’ price target indicates a potential upside of 19.88% from the stock’s previous close.

Several other research analysts have also commented on the stock. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Stock Performance

LNTH opened at $93.43 on Tuesday. The stock’s 50 day moving average price is $89.57 and its 200-day moving average price is $99.82. Lantheus has a 52-week low of $50.20 and a 52-week high of $126.89. The stock has a market capitalization of $6.50 billion, a PE ratio of 15.55 and a beta of 0.46.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Wilmington Savings Fund Society FSB bought a new position in shares of Lantheus during the third quarter valued at approximately $25,000. Signaturefd LLC grew its stake in shares of Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares during the last quarter. Nkcfo LLC bought a new position in Lantheus during the 2nd quarter valued at approximately $47,000. UMB Bank n.a. raised its stake in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after buying an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new stake in Lantheus in the third quarter worth $51,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.